menu
    • menu
    [{"orgOrder":0,"company":"Character Biosciences","sponsor":"aMoon","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Series B Financing","leadProduct":"CTX203","moa":"ABCA1","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Character Biosciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Character Biosciences \/ aMoon","highestDevelopmentStatusID":"5","companyTruncated":"Character Biosciences \/ aMoon"}]

    Find Clinical Drug Pipeline Developments & Deals by Character Biosciences

    Menu

    Character Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Character Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Character Biosciences

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTX203

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : aMoon

                            Deal Size : $93.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Character Biosciences Raises $93M Series B for Progressive Eye Diseases

                            Details : The financing aims to fund the clinical development of company's lead product CTX203, which is a potential first-in-class lipid-modulating agent designed for AMD.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            March 25, 2025

                            Lead Product(s) : CTX203

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : aMoon

                            Deal Size : $93.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth